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Involvement of the AP-1 (activator protein-1) transcription factor
has been demonstrated previously in the regulation of cell prolifer-
ation and cell-cycle progression, in the control of cell migration,
invasion and metastasis, and in signal transduction, stress respon-
siveness, DNA replication and DNA repair. YB-1 (Y-box-binding
protein-1) has also been implicated in many of these processes.
However, the mechanism by which YB-1 mediates these pro-
cesses is poorly understood. In the present study, we report that
overexpression of a transfected gene encoding YB-1 in human
HeLa cervical carcinoma cells significantly represses the trans-
activation of a minimal AP-1 reporter construct in response to
the tumour promoter PMA. YB-1 also represses mRNA ex-
pression and PMA-induced promoter transactivation of the endo-
genous AP-1 target gene encoding matrix metalloproteinase-12
(metalloelastase). YB-1 transrepression of both the minimal
and matrix metalloproteinase-12 promoter reporter constructs is
dependent on the AP-1 sequence. To identify new nuclear proteins
that bind specifically to the AP-1 DNA-binding site, we devised
a DNA-affinity-chromatography-based assay termed NAPSTER
(nucleotide-affinity preincubation specificity test of recognition)
and discovered a 49 kDa protein from human cancer cells that
binds in a sequence-specific manner to the AP-1 DNA sequence.
By tandem MS fragmentation sequencing analyses we determined
that p49 is a YB-1. Immunoblotting of the NAPSTER-purified p49
protein using anti-YB-1 antibodies confirmed YB-1 binding to the
AP-1 DNA sequence, as did gel mobility-supershift assays using
YB-1 antibodies. This is the first report of YB-1 transrepression
and interaction at the AP-1 DNA-binding site.
Key words: AP-1, DNA binding, matrix metalloproteinase-12,
NAPSTER, transactivation, YB-1.
INTRODUCTION
AP-1 (activator protein-1) proteins belong to the bZIP family
of transcriptional activators and are key mediators in the patho-
genesis of cancer and other disease states [1,2]. AP-1 co-ordi-
nately regulates the expression of target genes that control a
number of physiological processes within the cell, including cell-
cycle progression, tissue remodelling and invasion, and angio-
genesis, cell migration, cell differentiation and apoptosis. AP-1
proteins bind as dimers to a DNA sequence called the AP-1 DNA-
binding site or AP-1 site, with the consensus sequence 5′-TGAc/
gTCA-3′, which is usually located within the transcriptional
promoter regions of its target genes. AP-1 dimers are composed
of subunits from the jun and fos proto-oncogene families. The Jun
family consists of c-Jun, JunB and JunD, and the Fos family
consists of c-Fos, Fra-1, Fra-2 and FosB. The levels of jun
and fos mRNAs and proteins, as well as the DNA binding and
transactivation activities of AP-1 dimers, are regulated by tumour
promoters, growth factors, hormones, genotoxic agents and other
stimuli.
YB-1 (Y-box-binding protein-1) belongs to the YB protein fam-
ily that is distinguished by the presence of a cold-shock domain
[3]. YB-1 is expressed in multiple tissues. Its expression is up-
regulated in many tumours and is highly correlated with adverse
cancer prognosis and resistance to cancer drugs [4]. YB-1 is im-
plicated in RNA processing, chaperoning, stabilization and pack-
aging, in translational regulation and in chromatin modification.
Similar to AP-1, YB-1 has been implicated in transcriptional
activation and repression, cellular signalling, stress responsive-
ness, DNA replication and repair, and also in cell migration, in-
vasion, metastasis, cell proliferation and the cell cycle [3,5–7].
YB-1 binds to an inverted CAAT-box sequence termed the ‘Y-box’
and to several other DNA sequences in transcriptional promoters
that it regulates, both positively and negatively.
Because of the commonality of biological and biochemical
functions exerted by AP-1 and YB-1, it is logical to postulate that
YB-1 may execute some of its functions on an AP-1 pathway.
We now report that YB-1 represses transactivation of a minimal
AP-1 reporter construct in response to the tumour promoter PMA.
YB-1 also represses mRNA expression and promoter activation of
the AP-1 target gene MMP-12 (matrix metalloproteinase-12; also
known as metalloelastase) in real-time PCR and promoter reporter
assays. In the course of purifying new proteins that bind to the
AP-1 site, we found that YB-1 binds with sequence specificity to
the AP-1 DNA-binding site in a DNA-affinity-chromatography-
based NAPSTER (nucleotide-affinity preincubation specificity
test of recognition) assay [8,9] and in electrophoretic mobility-
shift assays.
EXPERIMENTAL
Reagents and cell lines
Reagents and supplies not described herein were purchased from
vendors cited in [10]. Human colon HT29 adenocarcinoma cells
and adherent human HeLa cervical carcinoma cells were obtained
from A.T.C.C. (Manassas, VA, U.S.A.) and were cultured as
described in [9].
Abbreviations used: AP-1, activator protein-1; β-gal, β-galactosidase; CMV, cytomegalovirus; GALV, gibbon ape leukaemia virus; β-gal, β-galactosidase;
GAPDH, glyceraldehyde-3-phosphate dehydrogenase; MMP-12, matrix metalloproteinase-12; NAPSTER, nucleotide-affinity preincubation specificity test
of recognition; NE, nuclear extract; Oct-1, octamer-1; wt, wild-type; YB-1, Y-box-binding protein-1.
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Figure 1 YB-1 represses PMA-induced AP-1 transactivation in HeLa cells
(A) AP-1 luciferase reporter constructs. Upper diagram: wt 3 × wtAP1-luc luciferase reporter construct; lower diagram: mutant 3 × mutAP1-luc reporter construct. ‘AdML’, adenovirus major late
basal promoter; ‘luc’, luciferase reporter gene. (B) AP-1 transactivation studies. HeLa cells were transiently co-transfected with either pcDNAFlagYB-1 or pcDNA3.1(+) vector control plasmid
plus wt or mutant (inset) AP-1 luciferase reporter constructs and pSVBgal plasmid. Cells were treated with PMA (TPA; 100 ng/ml) or DMSO solvent control for 24 h. All data are normalized to
β-gal activity. The percentage repression of induced activity is calculated as: 100× {(relative PMA-treated luc activity) − (relative PMA-treated, YB-1 transfected activity)}/{(relative PMA-treated
activity) − (relative PMA untreated activity)}. Error bars represent the S.E.M. for five independent experiments, each performed in duplicate. (C) YB-1 does not repress the transactivation of a
constitutive CMV-luc construct. HeLa cells were co-transfected with 2 µg of CMV-luc in the presence of 1 µg of pcDNAFlagYB-1 or vector control plasmid. Error bars represent the S.E.M. for three
independent experiments, each performed in duplicate. (D) FLAG–YB-1 protein expression. Expression of transfected YB-1 was confirmed by immunoblotting 10 µg of total protein from control
(pcDNA) and YB-1-transfected cells with anti-FLAG antibody. Numbering of the samples is the same as in (B). Equal protein loading was verified by immunoblotting with anti-GAPDH antibody.
Antibodies and immunoblotting
All anti-AP-1 antibodies were obtained from Santa Cruz Biotech-
nologies (Santa Cruz, CA, U.S.A.). Anti-YB-1 antibody was a
‘C1’ immunoaffinity-purified peptide antibody custom prepared
by Bethyl Laboratories (Woodlands, TX, U.S.A.; [11]). Anti-
FLAG M2 was obtained from Sigma (St. Louis, MO, U.S.A.)
and anti-GAPDH (where GAPDH stands for glyceraldehyde-
3-phosphate dehydrogenase) was from Research Diagnostics
(Flanders, NJ, U.S.A.). Western immunoblotting was performed
as described in [10] using antibodies at the following con-
centrations: anti-YB-1 (0.5 µg/ml), anti-FLAG (0.49 µg/ml) and
anti-GAPDH (0.4 ng/ml).
Plasmid constructs
pcDNAFlag-YB1 plasmid harbouring a full-length human
FLAG–YB-1 gene was a gift from Dr K. Kohno (University
of Occupational and Environmental Health, Kitakyushu, Japan).
A constitutive CMV (cytomegalovirus) overexpression construct
CMV-luc (CMV-luciferase) was constructed by subcloning the
firefly luciferase gene into the pcDNA3.1(+) plasmid at HindIII–
BamHI restrictions sites. The full-length constitutive pSVBgal
β-gal (β-galactosidase) overexpression construct was obtained
from Promega (Madison, WI, U.S.A.).
Minimal AP-1 reporter constructs
Oligonucleotides (‘oligos’) harbouring three tandem copies of
the wt (wild-type) (5′-agccagagaaatagatgagtcaacagc-3′; the AP-1
sequence underlined) or mutant (5′ agccagagaaatagaggagtctaca-
gc-3′; mutations in boldface) AP-1 DNA-binding site from the
GALV-LTR {GALV (gibbon ape leukaemia virus) long ter-
minal repeat [9]}, flanked by 5′-XhoI and 3′-BamHI restriction
sites, were custom synthesized (Integrated DNA Technologies,
Coralville, IN, U.S.A.) and subcloned into the pGL3AdML-Luc
at XhoI and BamHI sites by replacing 5× UASG sequences to
generate wt 3 × wtAP-1-luc and mut (mutant) 3 × mutAP-1-luc
luciferase reporter constructs, as depicted in Figure 1(A).
Promoter reporter constructs
Wt and mutant promoter reporter constructs pGL3-MMP-12-
luciferase and pGL3-MMP-12(AP-1mut)luciferase for the MMP-
12 gene were gifts from Dr M. Feinberg (Brigham and Women’s
Hospital, Boston, MA, U.S.A. [12]).
Luciferase reporter transactivation assay
HeLa cells were plated and transiently co-transfected with 2 µg
(for minimal reporter assays) or 1 µg (for promoter reporter
assays) of luciferase reporter plasmid, along with 1 µg of pcDNA-
FlagYB1 plus 200 ng of pSVBgal, using LipofectamineTM 2000
(1 µl/µg DNA; Invitrogen, Carlsbad, CA, U.S.A.). Cells that
received no transfected pcDNAFlagYB1 were transfected with
1 µg of pcDNA3.1(+) vector control plasmid (Invitrogen). Cells
were treated with PMA (100 ng/ml), 5 h after transfection.
Cells were assayed 24 h post-transfection for luciferase activity
(Roche Luciferase reporter gene assay kit; Roche, Indianapolis,
IN, U.S.A.) using a Packard Lumicount luminometer (Packard
Instruments, Downers Grove, IL, U.S.A.). β-Gal activity assays
were performed using a β-gal enzyme assay kit obtained from
Promega (Madison, WI, U.S.A.).
Preparation of whole cell lysates and NEs (nuclear extracts)
Whole cell lysates from HeLa cells and NEs from HT29 cells
were prepared as described in [8,9,13]. HeLa cells were plated at
3 × 106 cells/150 mm dish, treated with 100 ng/ml PMA for 24 h
and NE was prepared as described in [8,9].
NAPSTER AP-1 DNA-binding assays
Streptavidin beads (Pierce Biotechnology, Rockford, IL, U.S.A.).
were conjugated with biotinylated double-stranded oligos
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Table 1 Sequences of GALV wild-type and mutant oligos
AP-1 sites are underlined. Boldface letters denote mutated sequences.





GALV MUT 1 AGCACTCGAAATAGATGAGTCAACAGC
GALV MUT 2 AGCCAGATCCCTAGATGAGTCAACAGC
GALV MUT 3 AGCCAGAGAAAGCTCTGAGTCAACAGC
GALV MUT 4 AGCCAGAGAAATAGAGTCGTCAACAGC
GALV MUT 5 AGCCAGAGAAATAGATGATGACACAGC
GALV MUT 6 AGCCAGAGAAATAGATGAGTCACACTC
containing the 1× wt AP-1 GALV AP-1 sequence (same sequence
as used in the reporter construct mentioned above), or with a 28 bp
oligo containing four tandem 7 bp core AP-1 sites, as described in
[8,9]. Batchwise microscale AP-1 DNA affinity chromatographic
NAPSTER assays were performed using published methods [8,9].
Block mutants of the GALV AP-1 DNA sequences were prepared
as described by Powers et al. [14]. Sequences of the block mutants
are listed in Table 1.
DNA affinity purification and identification of p47 and p49 proteins
HT29 NE protein (60 mg) was dialysed against buffer Z and then
subjected to DNA affinity column chromatography with 2.5 mg of
mutant AP-1 DNA beads at 4 ◦C. The flowthrough was incubated
with 120 µg of poly(dI-dC) · (dI-dC) for 10 min on ice and split
into three portions: sample I, the starting material for purification
(54 mg of NE protein) and NAPSTER control samples II and III
(3 mg each of NE protein). Samples II and III were preincubated
with 375 µg of wt or mut competitor oligo in solution as described
in [9]. Streptavidin beads containing 2.7 mg of bound wt AP-1
DNA were added to sample I and beads containing 150 µg of
AP-1 DNA were added to samples II and III. Binding reactions
were performed as described in [9].
Bound proteins were eluted by incubating on a rotating clip
wheel twice for 30 min at 4 ◦C in 1 ml of buffer Z containing 1 M
KCl. They were then precipitated in 10% (v/v) trichloroacetic
acid, reprecipitated in absolute acetone (EM Science, Darmstadt,
Germany) and loaded on to SDS/polyacrylamide gel. The gels
were stained with Coomassie Brilliant Blue. Bands corresponding
to p49 and p47 were excised from sample I, as judged by their pre-
sence in samples I and III but not in sample II. p47 and p49 were
analysed by nanospray MS/MS fragmentation sequencing (tan-
dem MS fragmentation) at the Yale HHMI-Keck Laboratory as
described in http://info.med.yale.edu/wmkeck/prochem. Spectra
were searched manually and by using the Mascot peptide mass
‘fingerprint’ algorithm for protein identification (http://www.
matrix-science.com/search form select.html).
Gel-shift and supershift analyses
NE from MCF-7 breast cancer cells purchased from Santa Cruz
Biotechnology were used in gel-shift and supershift assays as
described by Phillips et al. [15] using 1× wt AP-1 oligos. Anti-
c-Jun and anti-YB-1 antibodies, and competitor peptide antigens
employed for supershift specificity controls, were obtained from
Santa Cruz Biotechnology.
Real-time PCR analyses
Real-time PCR was performed as described in [16] using HeLa
cells that had been treated with 100 ng of PMA for 24 h before
Table 2 Primers for real-time PCR analyses




harvesting mRNA. Primer sets used in real-time PCR are listed in
Table 2.
RESULTS
YB-1 transrepresses PMA-induced transactivation
of AP-1-dependent gene expression
To determine whether YB-1 may function on an AP-1 pathway,
we performed transactivation assays using minimal AP-1 reporter
constructs in PMA-stimulated HeLa cells that overexpressed a
transiently transfected YB-1 gene. Effects of YB-1 overexpression
on PMA-induced transactivation were compared between cells
transfected with wt reporter constructs versus reporter constructs
harbouring inactivating mutations in the AP-1 sites (see Figure 1A
for diagrams of wt and mutant AP-1 reporter constructs). PMA
treatment enhanced AP-1 transactivation of the wt AP-1 con-
struct in HeLa cells by 2.8-fold (Figure 1B), but had no effect on
the mutant AP-1 reporter construct. YB-1 overexpression caused
91% repression of PMA-induced AP-1 transactivation of the wt
AP-1 reporter. Repression of basal expression of the wt AP-1 re-
porter construct was also statistically significant, exhibiting 32%
inhibition. YB-1 did not repress the transactivation of the mutant
AP-1 reporter, demonstrating that YB-1 represses AP-1 gene
transactivation in a manner that is dependent on the AP-1 DNA se-
quence. Overexpression of transfected YB-1 caused only 5% re-
pression of transactivation from a constitutive CMV-luc construct
(Figure 1C). Overexpression of FLAG–YB-1 was confirmed
by immunoblotting with anti-FLAG-tagged antibodies (Fig-
ure 1D). Immunoblotting with an N-terminal antibody against
YB-1 (a gift from Dr C. Nelson, University of British Columbia,
British Columbia, Canada; [17]) demonstrated at least a 1.8-fold
increase in the levels of YB-1 protein after FLAG–YB-1 ex-
pression.
To investigate the possibility that overexpression of transfected
YB-1 represses transactivation by causing toxicity, we measured
the viability of the cells before and after YB-1 gene transfection.
Little change in cell number was observed after transfection with
YB-1 as measured by counting the cells in a haemocytometer
and by immunoblotting equal volumes of the extract used in
transactivation assays with anti-GAPDH antibodies (Figure 1D
and results not shown). Approximately 97–98.5% of the cells
remained viable in Trypan Blue exclusion assays after transfection
of YB-1. These results rule out the possibility that YB-1 trans-
repression of AP-1-dependent gene expression occurs through a
non-specific toxic mechanism.
Transrepression of AP-1-dependent gene expression does not
occur by YB-1 down-regulation of AP-1 subunit protein levels
It is possible that YB-1 could repress AP-1 transactivation by a
pathway that ultimately decreases the availability of AP-1 proteins
for binding the AP-1 site. One pathway to achieve this could
be to reduce the steady-state intracellular concentrations of one
or more AP-1 subunits. HeLa cells were transiently transfected
with YB-1 and the intracellular levels of all seven AP-1 subunit
proteins were measured (Figure 2A). Expression of transfected
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Figure 2 No effect of YB-1 on intracellular levels or nuclear localization of
AP-1 subunits
(A) Overexpression of transfected YB-1 does not affect the intracellular levels of AP-1 subunits;
4.5 × 105 HeLa cells plated on 150 mm tissue culture dishes were transiently transfected with
20 µg of pcDNA3.1 or pcDNAFlag-YB-1 constructs. Whole cell lysates (10 µg/sample) were
prepared after 24 h of PMA treatment (100 ng/ml, ‘+’) or with DMSO control solvent (‘−’) and
immunoblotted with antibodies raised against the seven AP-1 subunits and with anti-FLAG
antibody. (B) Overexpression of transfected YB-1 does not alter nuclear concentrations of AP-1
subunits. HeLa cells were transfected, treated with PMA (TPA) and fractionated to separate
the cytosolic and nuclear compartments. NE or cytosol were loaded in SDS/PAGE using NE and
cytoplasmic samples derived from 4 × 105 cells in each lane to equalize the number of cellular
equivalents per test sample. Samples were immunoblotted with antibodies raised against the
seven AP-1 subunits, with anti-Oct-1 and with anti-FLAG. C, cytosol.
YB-1 was confirmed by immunoblotting with anti-FLAG-tagged
antibodies. Transfection efficiency was estimated to be in the
range 75–90% on the basis of the percentage of HeLa cells that
incorporated green fluorescent protein plasmid, as detected by in-
direct immunofluorescence microscopy. Intracellular levels of the
seven AP-1 subunits were not altered by overexpression of
the transfected YB-1. These results rule out the possibility that
YB-1 down-regulates steady-state intracellular levels of any of
the AP-1 subunits by any of the following means: (i) down-regu-
lating the transcription of genes encoding AP-1 subunits, (ii) up-
regulating the rate of degradation of jun and fos mRNAs, (iii) in-
hibiting the cytoplasmic transport of jun and fos hnRNAs,
(iv) inhibiting AP-1 protein translation and (v) up-regulating AP-1
protein degradation.
YB-1 does not block the entry of AP-1 into the nucleus
YB-1 could also limit the availability of AP-1 subunits for binding
the AP-1 site by inhibiting the entry of AP-1 proteins into the
nucleus. To test this hypothesis, we transfected HeLa cells with
YB-1 and then measured the levels of all seven AP-1 subunits in
the nuclear and cytoplasmic fractions (Figure 2B). No change
in subcellular distribution or total intranuclear levels of any of the
AP-1 subunits was observed on overexpression of the transfected
YB-1. Immunoblotting with an antibody raised against the Oct-1
(octamer-1) transcription factor, a marker for nuclear localization,
demonstrated exclusive localization of Oct-1 to the nucleus,
confirming that intact subcellular fractions were isolated. These
results rule out the hypothesis that YB-1 represses transactivation
by decreasing the intranuclear concentrations of AP-1 proteins
available to implement AP1-dependent transactivation.
NAPSTER DNA affinity chromatography: purification of YB-1 as a
protein that interacts with the AP-1 sequence
While performing transactivation studies, we were engaged in a
project whose purpose was to isolate and identify new proteins
that bind to the AP-1 DNA sequence. We performed AP-1 DNA
affinity chromatography to identify such proteins. To distinguish
proteins that bind specifically to the AP-1 DNA sequence from
proteins that bind non-specifically to DNA or to chromato-
graphy beads, we used the NAPSTER assay. NAPSTER consists
of three samples. Nuclear extracts either directly undergo DNA
affinity chromatography with an AP-1 DNA sequence conjugated
with streptavidin beads (sample ‘I’ in all NAPSTER experi-
ments) or are first preincubated with excess unconjugated wt
(sample ‘II’) or mutant AP-1 oligonucleotide (oligo; sample ‘III’)
before chromatography. Batchwise microscale DNA affinity
chromatography is then performed, by methods adapted from
Lee et al., with numerous modifications [8,9,18]. Samples
from NAPSTER isolation are subsequently loaded in SDS/PAGE
and subjected to immunoblotting with antibodies raised against
the proteins of interest. When performing NAPSTER using strept-
avidin affinity beads conjugated with a wt GALV AP-1 oligo, we
observed the specific binding of all seven Jun and Fos family AP-
1 subunits to the AP-1 site. The results were reproducible, thus
demonstrating the efficacy of the method (Figure 3A).
When purification by NAPSTER DNA affinity chromatography
is performed followed by Coomassie Blue staining, two proteins
of 47 and 49 kDa are reproducibly observed that bind the GALV
AP-1 beads in samples I and III, but at much decreased levels in
sample II (Figure 3B). Initially, we hypothesized that p47 and p49
were AP-1 subunits since they are in the molecular-mass ranges
of these proteins. To test this hypothesis, Coomassie Blue-stained
p47 and p49 gel bands were purified and immunoblotted with a
mixture of antibodies raised against all seven Jun/Fos AP-1 pro-
teins. Despite immunoblotting of Coomassie Blue-stained
quantities of p47 and p49, no AP-1 signal was detected, indicating
that p47 and p49 are not AP-1 proteins (Figure 3C).
Coomassie Blue-stained p47 and p49 from sample I purified
from HT29 NE protein then underwent tandem MS fragmen-
tation sequencing analyses. For p49, two peptides were isolated,
with the sequences AEAANVTGPGGVPVQHSK and SVG-
DGETVEFDVVEGEK, both of which matched YB-1 in Mascot
peptide mass ‘fingerprint’ analyses of the tandem MS fragmen-
tation data. Peptides with the sequences SVGDGETVEFDVV-
EGEK and NGYGFINR, matching YB-1 in the Mascot procedure,
were identified from analyses of p47.
Confirmation of the tandem MS fragmentation data was then
sought by performing immunoblotting of NAPSTER-purified NE
material using anti-YB-1 antibody. YB-1 antibody specifically
recognized the YB-1 protein in affinity chromatographically puri-
fied samples I and III of the NAPSTER, but not in sample II in both
HT29 and HeLa NE (Figure 4A). Specific YB-1 binding to the
AP-1 site was observed in HT29 and HeLa NEs in 81 independent
experiments. Preincubation of YB-1 antibody with YB-1 peptide
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Figure 3 NAPSTER analyses of AP-1, p47 and p49 proteins
(A) Jun family and Fos family AP-1 subunit proteins bind specifically to the AP-1 DNA
in NAPSTER. NAPSTER samples I, II and III originating from 700 µg of HT29 NE protein
were generated, each split into seven individual fractions, run on an SDS/polyacrylamide gel
alongside 30 µg of NE protein. Samples were then immunoblotted with each of the seven
anti-AP-1 antibodies. Names to the left of autoradiograms indicate identities of Jun and Fos
family antibodies used in immunoblotting analyses. (B) p47 and p49 proteins bind specifically
to AP-1 DNA in NAPSTER. NAPSTER samples I, II and III were generated as described in the
Experimental section and subjected to SDS/PAGE. The gel was stained with Coomassie Brilliant
Blue. (C) p47 and p49 are not AP-1 proteins. p47 and p49 proteins were purified from sample I
by NAPSTER and SDS/PAGE starting with 15 mg of NE protein, as described in the Experimental
section. p47 and p49 were excised from the gel and loaded on to a second gel alongside 30 µg
of HT29 NE extract protein (NE, first lane). Samples were immunoblotted with a mixture of all
seven AP-1 antibodies.
antigen abrogated YB-1 antibody recognition of YB-1 protein,
whereas preincubation with a non-specific peptide did not (results
not shown), indicating that YB-1 antibody recognition of YB-1
protein is specific. YB-1 binding to the AP-1 site was competed
by increasing the titrated concentrations of wt AP-1 oligo but not
doubly mutated AP-1 oligo (Figure 4B).
The p47 protein was reproducibly recovered along with
p49 protein and detected by Coomassie Blue staining when
NAPSTER purifications were performed that involved several
tandem purification steps. In contrast, in small-scale single-step
NAPSTERs, we visualized the p49 band in every experiment,
and the p47 band in just three out of 81 experiments (results not
shown). The procedure employed to isolate YB-1 for Coomassie
Blue staining and sequencing involves more steps and sample
handling time compared with analytical NAPSTER assays, which
consist of a single purification step. Since more extensive sample
handling creates increased opportunity for sample degradation,
we hypothesize that p47 may be a proteolytic digestion product
or a hypophosphorylated form of YB-1 that is generated during
the purification of p49 protein.
Since YB-1 binding to single-stranded DNA sequences has
been described in [19], NAPSTER was performed using AP-1
DNA beads that had been prepared by incubating a 5-fold molar
excess of unbiotinylated AP-1 oligo with the biotinylated com-
plementary strand before conjugating the double-stranded AP-1
oligo with streptavidin beads. The intensity and specificity of the
YB-1-binding signal in NAPSTER assays employing these beads
were equal to those of beads conjugated with AP-1 DNA that
had been annealed using a 1:1 ratio of the two strands (results not
shown), showing that YB-1 binds to a double-stranded AP-1 site.
YB-1 binds to AP-1 oligonucleotides in gel-supershift assays
We then sought to confirm the binding of YB-1 observed in
NAPSTER by performing gel-shift analyses with anti-YB-1 anti-
bodies (Figure 4C). A specific AP-1 shift was identified by pre-
incubation of excess wt or mut AP-1 oligos with NE before the
addition of labelled wt AP-1 oligo. Supershift assays were per-
formed by preincubating NE with anti-c-Jun or anti-YB-1 before
the addition of labelled oligo. Both anti-c-Jun and anti-YB-1
gave rise to supershifted protein–DNA complexes. In samples
incubated with anti-c-Jun or anti-YB-1 antibodies, the sum of
the intensities of the supershifted band and the shifted band is
significantly less than the intensity of the shifted band in control
samples incubated without antibodies. This suggests that anti-
c-Jun and anti-YB-1 each concomitantly cause a supershift and
Figure 4 YB-1 binds specifically to an AP-1 site in NAPSTER and gel-shift assays
(A) Confirmation that p49 is YB-1 in NAPSTER; 300 µg of either HeLa (upper panel) NE protein or HT29 (lower panel) NE protein for each of the samples I, II and III was subjected to NAPSTER
and immunoblotted with anti-YB-1. (B) Wt but not mutant AP-1 DNA competes for YB-1 binding as a function of increasing concentration; 150 µg of HT29 NE per sample was preincubated for
15 min with increasing fold molar excess of unconjugated wt or mut AP-1 oligo before the addition of 10 µg of wt AP-1 oligo on beads. Triangles above autoradiograms indicate increasing molar
quantities of unconjugated competitor preincubation oligos relative to oligo on beads. ‘wt’, wt unconjugated competitor oligo3; ‘mut’, mutant unconjugated competitor oligo. ‘–’, no competitor oligo.
Consecutive lanes for wt and mut lanes contained 0.1-, 0.2-, 0.5-, 0.8-, 1.5- and 2.5-fold molar excess of oligo respectively. (C) YB-1 binds the AP-1 site in gel-shift assays. Shifted and supershifted
bands are indicated by arrows. Duplicate gel-shift samples are shown in brackets. #1, AP-1 shift, no competitor oligo preincubation; #2, wt competitor oligo preincubation; #3, mutant competitor
oligo preincubation; #4, anti-c-Jun; #5, anti-c-Jun + c-Jun peptide; #6, anti-YB-1; #7, anti-YB-1 + YB-1 peptide. (D) The core AP-1 element is sufficient for YB-1 binding; 300 µg of HeLa NE
protein for each of samples I, II, and III were subjected to NAPSTER using streptavidin beads conjugated with the 3 × wtAP-1 oligo (the 3 × GALV-AP-1 sequence, left bracket) or with a 28 bp oligo
containing four multimerized 7 bp core AP-1 sites (5′-TGAGTCA-3′; ‘core AP-1’, right bracket). Competitions for samples II and III were performed with 2.5-fold molar excess of unconjugated wt or
mutant 3 × wtAP-1 oligo (left bracket) or with wt or mutant core AP-1 (right bracket). Mutated core AP-1 sequences contain four tandem doubly mutated AP-1 sites (5′-GGAGTCT-3′ ; mutations
underlined and shown in boldface).
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Figure 5 Mutational mapping of the YB-1-binding site
(A) Schematic representation of block mutations in the GALV 1 × AP-1 oligo. The line indicates
GALV AP-1 oligo and the box shows the AP-1 sequence. 5′ and 3′ with asterisks demonstrate
the locations of point mutations introduced in the AP-1 site. Numbered brackets indicate the
locations of block-mutated sequences introduced along the length of the oligo. (B) YB-1 binding
to the GALV AP-1 oligo involves sequences 3, 4 and 5 but not sequences 1, 2 and 6. NAPSTER
analyses were performed for samples I, II and III using no competitor (lane I) or a 2.5-fold molar
excess of wt (II) or doubly mutated (III) competitor oligo (lanes II and III); or using competitor
oligos containing mutations in blocks 1–6 as indicated by the numbered lanes. (C) 5′- and
3′-nucleotides in the core AP-1 sequence are important for YB-1 binding to the core AP-1 site in
the GALV AP-1 oligo. NAPSTERs were performed for wt (lane II) or doubly mutated competition
oligos (lane III) or AP-1 oligos mutated in the 5′- or 3′-AP-1 nucleotide as indicated above the
lanes. (D) JunD binding to the GALV AP-1 sequence involves only the AP-1 site. NAPSTER was
performed using competitor oligos harbouring block mutations or point mutations as described
above for (B, C), after which immunoblotting was performed with anti-JunD antibodies.
a partially blocked AP-1 shift. Controls for antibody specificity
were performed by preincubating anti-c-Jun and anti-YB-1 with
excess cognate peptide antigen competitor, which abrogated the
c-Jun and YB-1 supershifts and caused the return of the AP-1
shifts to their original intensities. Preincubation of αYB-1 with
heterologous peptide antigens from the ERK3 protein did not
inhibit the supershift or blocked the shift caused by anti-c-Jun
and anti-YB-1 antibodies. YB-1 binding to a Y-box motif in the
human multidrug resistance-1 promoter was also observed in gel-
shift assays (results not shown). Results of gel-shift assays confirm
the NAPSTER data, demonstrating that YB-1 binds to oligos
containing the AP-1 DNA sequence.
Sequence requirements for YB-1 binding to AP-1 oligonucleotides
In addition to observing YB-1 binding to the GALV AP-1 oligos in
NAPSTER, we also observe specific YB-1 binding to the GCN4
AP-1 site, which has flanking sequences that differ from those
of the GALV AP-1 DNA (results not shown). YB-1 binding is also
observed in NAPSTER using a synthetic 28 bp sequence contain-
ing four multimerized copies of the core 7 bp 5′-TGAGTCA-3′ se-
quence, indicating that the core AP-1 sequence lacking flanking
sequences is sufficient for YB-1 binding (Figure 4D). Binding of
JunD to the GCN4 and core AP-1 sequences was also observed
(results not shown).
Although these results indicate that flanking sequences are not
required for YB-1 binding to the AP-1 site, it is still possible that
they may facilitate YB-1 binding. To investigate this notion, a
set of six GALV oligos mutated in six consecutive blocks from
the 5′-end to the 3′-end was generated by substituting inverse
complementary bases in adjacent consecutive sets of 4 bp (Fig-
ure 5A and Table 1). Each of these block mutants was used as com-
petition DNA in NAPSTER assays using GALV beads harbour-
ing the wt AP-1 site. Importance of each of the sequences in the
block mutants for YB-1 binding was compared by assessing the re-
lative intensities of bands visualized after using the mutated oligos
in NAPSTER, where a band of dark intensity indicates that the
sequence in question is important for protein binding, and a light
band indicates that the sequence is not important. As shown in
Figure 5(B), three block mutations in the GALV-flanking region,
namely mutants 1, 2 and 6 in the 5′-end, middle and 3′-end
of the GALV sequence, do not decrease their effectiveness as
competitor oligos in NAPSTER. This indicates that these se-
quences do not bind YB-1. However, mutagenesis of block 3, the
TAGA sequence immediately adjacent to the 5′-end of the core
AP-1 site, significantly impairs the potency of the GALV AP-1 se-
quence as a NAPSTER competitor oligo, indicating that this
sequence does associate with YB-1. Block mutagenesis of core
AP-1 blocks 4 and 5 located in the 5′-half and the 3′-half of
the AP-1 site significantly decreases their potencies as competitors
in NAPSTER, indicating that both sequences are important for
YB-1 binding. Furthermore, oligos harbouring mutations in only
the 5′-base of the core AP-1 site (GGAGTCA, the mutated base
is underlined) and oligos harbouring a mutation in the 3′-base (TG-
ACTCT, mutated base underlined) each exhibit partial competi-
tion relative to doubly mutated AP-1 oligos (TGACTCT; compare
lanes labelled 5′ and 3′ with lane III of Figure 5C), suggesting
that both bases are required for optimum YB-1 binding. Intensity
of the band for the 5′-mutant competition was somewhat
higher than that of the 3′-mutant competition in some experiments.
Similar to YB-1, JunD does not bind to blocks 1, 2 and 6 and
binds to blocks 4 and 5, but unlike YB-1, JunD does not bind to
block 3 (Figure 5D). Taken together with the data in Figure 4(D)
demonstrating that the core AP-1 site is sufficient for specific
YB-1 binding, the data in Figure 5 indicate that YB-1 binds both
to the core AP-1 site and to the adjacent 5′-flanking sequence.
YB-1 represses PMA transactivation of the MMP-12 gene
Since YB-1 represses transactivation at an AP-1 site and binds
to an AP-1 DNA sequence, we hypothesized that it would down-
regulate promoter activity and mRNA expression of an endo-
genous AP-1 target gene. MMP-12 is an AP-1 target gene that
encodes a major extracellular matrix MMP that degrades elastase
in the extracellular matrix. Promoter reporter constructs from the
MMP-12 gene containing one wt or one mutated AP-1 site were
transiently co-transfected into HeLa cells with FLAG–YB-1 or
with pcDNA vector control construct. Treatment with PMA re-
sulted in 4.2-fold activation of the MMP-12 promoter reporter
(Figure 6A). Mutation of the AP-1 site blocks PMA activation.
YB-1 represses PMA-induced wt MMP-12 promoter activity by
61%. Activity of the mutated MMP-12 promoter construct is not
inhibited by YB-1. These results show that YB-1 mediates the
repression of the MMP-12 promoter through the AP-1 site.
Real-time PCR analyses were performed to quantify steady-
state mRNA expression levels of MMP-12 in the presence and
absence of YB-1 overexpression (Figure 6B). Transfected FLAG–
YB-1 caused a 30-fold increase in YB-1 mRNA expression. YB-1
overexpression caused 2.5-fold repression of MMP-12 expres-
sion. Control studies demonstrated that YB-1 did not affect the
mRNA expression of GAPDH, which is not an AP-1 target gene.
DISCUSSION
YB-1 has several biochemical and biological functions that over-
lap with AP-1, since both proteins have nucleic acid binding and
transcription-regulatory activities and have been implicated in
mediating DNA repair, cell cycle, cell proliferation and neoplastic
transformation [3,20]. Overlapping biological functions of YB-1
and AP-1 may be attributable in part to DNA binding and trans-
repression activities of YB-1 at the AP-1 site. YB-1 is also
implicated in mediating RNA processing, stabilization, chaperon-
ing and packaging, and in RNA translation. Roles for YB-1
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Figure 6 YB-1 represses the AP-1-dependent transactivation and mRNA
expression of the MMP-12 gene
(A) YB-1 represses PMA transactivation of the MMP-12 gene promoter at the AP-1 site. HeLa
cells were transiently co-transfected with 1 µg of wt or AP-1 mutant MMP-12 promoter reporter
constructs plus pcDNAFlagYB-1 or pcDNA 3.1(+) vector control along with pSVBgal plasmid.
Transfection conditions, PMA (TPA) treatment and data analyses were as described in the
Experimental section and in the legend to Figure 1. Error bars represent the S.E.M. for four
independent experiments, each performed in duplicate. (B) YB-1 represses mRNA expression
of the MMP-12 gene in real-time PCR analyses. Error bars represent the S.E.M. for three
independent experiments.
in such a broad range of functions implies that an important
activity for YB-1 may be the co-ordinated integration of transcrip-
tion, replication and translation, such that it may orchestrate
complex biological processes such as cell proliferation.
Since, in many contexts, AP-1 transactivation mediates neo-
plastic transformation, YB-1 transrepression of AP-1-dependent
gene expression appears paradoxical in the light of results from
many groups correlating YB-1 expression with malignant pro-
gression. This paradox is addressed in a recent study by Bader
et al. [21], who found that expression of transfected YB-1 inhibits
neoplastic transformation of chick-embryo fibroblasts, indicating
a tumour suppressor function for YB-1. A tumour suppressor
function for YB-1 is consistent with its transrepressing activity.
Several other genes that display tumour suppressor function also
exhibit increased expression as a function of malignant pro-
gression [22,23].
YB-1 has been shown to mediate both transcriptional activation
and repression of a number of genes [3]. YB-1 has been found to
transactivate promoters of the genes encoding the P-glycoprotein
MDR-1 multidrug-resistance gene and the myosin light chain 2v,
both through the Y-box sequence. YB-1 has been shown to bind
to a Y-box and repress transactivation of the procollagen α1(I)
and α2(I) genes [5]. The present study is the first to demonstrate
that YB-1 represses the transactivation of gene expression at the
AP-1 site. It is also the first to report that YB-1 can repress the ex-
pression and transactivation of the MMP-12 gene.
The present study is the first to report physical association
of YB-1 with the AP-1 DNA-binding site. In addition to the Y
box, YB-1 is capable of binding to and regulating transcription
at a number of other sequences, including several nucleotide
sequences in RNA, single-stranded DNA and double-stranded
DNA. YB-1 recognizes duplex DNA with strong purine/pyrim-
idine asymmetry and binds preferentially to the pyrimidine-rich
strand in several genes [24]. The mechanism by which YB-1 binds
to diverse sequence motifs is not known. One possible mechanism
is that YB-1 dimerizes or forms higher-order multimers with many
different proteins and that these different complexes have distinct
DNA-binding specificities.
AP-1 was originally purified in groundbreaking studies per-
formed in 1987 employing purification schemes that involved
DNA affinity chromatography [18,25]. Whereas the predominant
species identified in those purifications was AP-1, YB-1 binds in
much greater abundance compared with AP-1 in NAPSTER.
HeLa NEs were used in one of the original purification studies,
and YB-1 from HeLa NE has AP-1 DNA-binding activity in
NAPSTER. It is possible that YB-1 was co-purified along with
AP-1 components in the original purifications. In the original
studies, multiple silver-stained bands were visualized with mol-
ecular masses in the same range as YB-1. One of them could
have been YB-1. The original work on AP-1 antedated protein
microsequencing technology, so the actual cloning of Jun proto-
oncogenes occurred through indirect studies in which mammalian
cDNA homologues of the v-jun oncogene were cloned because
v-Jun, similar to purified AP-1 proteins, was found to bind the
AP-1 DNA sequence [26]. By these means, YB-1 binding to
the AP-1 site may have been visualized in silver-stained gels,
but not pursued or identified. It may also be that YB-1 was not
recovered in the original purifications. Whereas the NAPSTER
purification used to isolate YB-1 consists only of several steps, the
original methods used to isolate AP-1 had multiple steps, includ-
ing precipitation with ammonium sulphate, molecular sieve
chromatography, heparin affinity chromatography and stepwise
KCl elution after DNA affinity chromatography. These additional
steps may have removed YB-1 from these preparations.
A number of bZIP proteins of the AP-1 superfamily bind
with sequence specificity to the minimal 5′-TGAg/cTCA-3′ AP-1
consensus sequence, either in the presence or absence of AP-1 pro-
teins [27,28]. These include members of the Nrf, Maf and
CREB/ATF families. SFA-2 and SNFT bZIP proteins bind the
AP-1 site when heterodimerized with c-Jun [29,30]. BZLF1 (also
known as ZEBRA), a divergent member of the bZIP family,
also binds to the minimal consensus AP-1 site, either unaccom-
panied or in a complex with c-Fos and transcriptionally activates
gene expression [31]. SNFT, JDP2, CREB and CREM bZIP AP-1
superfamily members bind to the AP-1 site and repress gene
transactivation. A variety of non-bZIP transcription-regulatory
factors can also repress AP-1 transactivation. Included among
these are YY1, PE1, p300, Bcl-6, MyoD, menin, p202, Ets and
several members of the nuclear receptor superfamily (e.g. peroxi-
some proliferator receptor, glucocorticoid receptor and retinoic
acid receptors RAR and RXR; see [32,33] for reviews). Interaction
of these molecules with the AP-1 site has not been demonstrated
and, in many cases, has been ruled out. To our knowledge, YB-1
is the first non-bZIP protein outside the AP-1 superfamily that
associates with the AP-1 site and represses AP-1 transactivation.
NAPSTER DNA-binding data indicate that the core AP-1 con-
sensus sequence is sufficient for specific YB-1 binding to the AP-1
site. Sequences in flanking regions of the DNA are not required
for YB-1 to bind to the AP-1 site. Nevertheless, we also found
that bases within the TAGA sequence in the 5′-flanking region
immediately adjacent to the AP-1 site mediate YB-1’s association
with the GALV oligo. Taken together, these results suggest that the
GALV oligo contains two adjacent sequences involved in YB-1
binding, comprising the AP-1 site and the adjoining 5′-flanking
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TAGA sequence. YB-1 repression of transactivation at the GALV
core AP-1 site is abrogated 100% by the introduction of mu-
tations into the AP-1 site, indicating that the AP-1 site is re-
quired to mediate YB-1 transregulation of the GALV sequence.
Efficient YB-1 transrepression can occur without GALV flanking
sequences, since we also observe 80% transrepression of a GCN
AP-1 reporter, whose sequences flanking the AP-1 site are unrel-
ated to those of the GALV sequence (results not shown).
It is probable that more YB-1 than AP-1 binds in NAPSTER
since YB-1 is much more abundant compared with AP-1. Abun-
dant proteins such as YB-1 may interact with specific sequences
with lower affinity and provide a strategy for basal transcriptional
repression. Several AP-1 transcriptional repressors have been the
subjects of intense interest, partly due to their potential clinical
applicability [32–34]. For example, glucocorticoids and retinoids
are widely studied for their abilities to bind their respective re-
ceptors, repress AP-1 transactivation and exert powerful antipro-
liferative and chemopreventative effects.
Because de-regulated AP-1 transcriptional activity has been
shown in many instances during the pathogenesis of cancerous,
cardiovascular and neurological disease states, YB-1 repression of
AP-1 transactivation may be important for its potential ability to
mediate these processes. Similar to AP-1, both YB-1 and MMP-
12 have been found to be mediators of invasion and metastasis
[1–3,5,7]. Regulation of MMP-12 expression by YB-1 through the
AP-1 site suggests that an interplay may exist between AP-1, YB-
1 and MMP-12 to regulate these important biological processes.
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